Front-line targeted therapy for advanced EGFR-positive disease

Biomarker-Positive Disease: Approach to Selecting Targeted Therapies in Lung Cancer and Beyond.Подробнее

Metastatic lung cancer | Treatment of stage IV lung cancer | Immunotherapy | Targeted therapyПодробнее

Full Event Mainstage 2023 Targeted Therapies in Lung Cancer Patient Forum ON-DEMANDПодробнее

Targeted Therapy in Non-Small Cell Lung CancerПодробнее

Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLCПодробнее

Novel combinations in EGFR positive advanced NSCLCПодробнее

Advanced NSCLC: Refining Clinical Pathways in the Rapidly Evolving Therapeutic LandscapeПодробнее

Addressing Key Targets in Advanced NSCLC: HER2-, HER3-, and TROP2-Targeted TherapiesПодробнее

Testing for Common and Uncommon EGFR Mutations to Guide EGFR-Targeted Therapy in NSCLCПодробнее

Time for Even More Precision in Testing and Treatment of EGFR-Mutated NSCLCПодробнее

Advances in Frontline Therapy for EGFR+ NSCLCПодробнее

Gene Targeted Therapy for Non Small Cell Lung CancerПодробнее

Targeted treatment with EGFR TKIs: Front line optionsПодробнее

Osimertinib as First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC? (BMIC-017)Подробнее

Molecular Targeted Therapies for Advanced HCCПодробнее

Osimertinib as Frontline Therapy for EGFR-Positive NSCLCПодробнее

Frontline Therapy for EGFR Plus NSCLC: Osimertinib’s ImpactПодробнее

NSCLC: Integrating EGFR-Inhibiting Therapies into Clinical Pathways for First-Line TreatmentПодробнее

Osimertinib As Frontline Therapy in EGFR-Positive NSCLCПодробнее